Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis

Pathophysiology

Volumn 22, Issue 1, 2015, Pages 65-71

  Susianti, Hani ^a   Iriane, Vincentia M ^a   Dharmanata, Suriya ^a   Handono, Kusworini ^a   Widijanti, Anik ^a   Gunawan, Atma ^a   Kalim, Handono ^a  

^a BRAWIJAYA UNIVERSITY   (Indonesia)

Author keywords

Lupus nephritis; UIL 17; UMCP 1; UNGAL; UTGF 1

Indexed keywords

INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NON INVASIVE MEASUREMENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

EID: 84922847714     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2014.12.003     Document Type: Article

References (23)

1. Harrison's Principle of Internal Medicine 2012, 1596-1611. McGraw Hill, USA. 18th ed. D.L. Longo, D.L. Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, J. Loscalzo (Eds.).
2. Avihingsanon Y., Hirankarn N. Major lupus organ involvement: severe lupus nephritis. Lupus 2010, 19:1391-1398.
3. Dooley M.A. Clinical and laboratory features of lupus nephritis. Dubois' Lupus Erythematosus 2007, 1112-1124. Lippincott Williams & Wilkins, Philadelphia. 7th ed. D.J. Wallace, B.H. Hahn (Eds.).
4. Ortega L.M., Schultz D.R., Lenz O., Pardo V., Contreras G.N. Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010, 19:557-574.
5. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 294:F697-F701.
6. Cheng J., Encarnacion M.M.D., Warner G.M., Gray C.E., Nath K.A., Grande J.P. TGF-β1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am. J. Physiol. Cell Physiol. 2005, 289:C959-C970.
7. Saxena V., Lienesch D.W., Zhou M., Bommireddy R., Azhar M., Doetschman T. Dual role of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. J. Immunol. 2008, 180:1903-1912.
8. Nalbandian A., Crispín J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 2009, 157:209-215.
9. Suzuki M., Wiers K.M., Gitelman M.S., Haines K.A., Olson J., Onel K.B. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr. Nephrol. 2008, 23:403-412.
10. Wasilewska A., Zwierz W.Z., Janusz K.T., Kolodziejczyk Z. Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand. J. Urol. Nephrol. 2011, 45:52-59.
11. Contreras G., Pardo V., Cely C., et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005, 14:890-895.
12. Yamamoto K., Loskutoff D.J. Expression of transforming growth factor-β and tumor necrosis factor-α in the plasma and tissues of mice with lupus nephritis. Lab. Invest. 2000, 80(10):1561-1570.
13. Houssiau F.A. Management of lupus nephritis: an update. J. Am. Soc. Nephrol. 2004, 15:2694-2704.
14. Marks S.D., Williams S.J., Tullus K., Sebire N.J. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in paediatric lupus nephritis. Nephrol. Dial. Transplant. 2008, 23:3521-3526.
15. Marks S.D. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr. Nephrol. 2010, 25:2283-2288.
16. Mok C.C. Biomarkers for lupus nephritis: a critical appraisal. J. Biomed. Biotechnol. 2010, 2010:638413. (article ID 638413).
17. Rovin B.H., Birmingham D.J., Nagaraja H.N., Yu C.Y., Hebert L.A. Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Joint Dis. 2007, 65(3):187-193.
18. Rovin B.H., Zhang X. Biomarkers for lupus nephritis: the quest continues. Clin. J. Am. Soc. Nephrol. 2009, 4:1858-1865.
19. Chan R.W.Y. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol. Dial. Transplant. 2006, 21:1534-1540.
20. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand. J. Clin. Lab. Invest. 2008, 241:89-94.
21. Alunno A., Bartoloni E., Bistoni O., Nocentini G., Ronchetti S., Caterbi S., Valentini V., Riccardi C., Gerli R. Balance between regulatory T and Th7 cells in systemic lupus erythematosus: the old and the new. J. Immunol. Res. 2012, 2012:823085. (article ID 823085).
22. Mishra J., Dent C., Tarabishi R., Mitsnefes M.M., Ma Q., Kelly C., Ruff S.M., Zahedi K., Shao M., Bean J., Mori K., Barasch J., Deavarjan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
23. Brunner H.I., Bennett M.R., Mina R., Suzuki M., Petri M., Kiani A.N., Pendl J., Witte D., Ying J., Rovin B.H., Devarajan P. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012, 64(8):2687-2697.